Logo

SSII

SS Innovations International, Inc.

SSII

SS Innovations International, Inc. • NASDAQ
$6.73 ▲ 4.83% (+0.31)
Market Cap $1.30 B
52w High $22.42
52w Low $3.02
Dividend Yield 0%
P/E -112.17
Volume 19.86K
Outstanding Shares 193.62M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $12.829M ▲ $8M ▲ $-3.718M ▼ -28.98% ▼ $-0.019 ▼ $-1.397M ▼
Q2-2025 $10M ▲ $5.818M ▼ $-256.691K ▲ -2.567% ▲ $-0.001 ▲ $574.199K ▲
Q1-2025 $5.121M ▼ $7.009M ▼ $-5.681M ▲ -110.951% ▲ $-0.032 ▲ $-5.093M ▲
Q4-2024 $5.624M ▲ $10.661M ▲ $-7.452M ▼ -132.51% ▼ $-0.044 ▼ $-7.202M ▼
Q3-2024 $4.387M $5.522M $-3.245M -73.988% $-0.036 $-2.878M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $11.706M ▲ $69.577M ▼ $29.928M ▲ $39.649M ▼
Q2-2025 $11.375M ▼ $69.978M ▲ $27.955M ▲ $42.023M ▲
Q1-2025 $15.873M ▲ $63.457M ▲ $22.903M ▼ $40.554M ▲
Q4-2024 $466.5K ▲ $42.385M ▲ $28.928M ▲ $13.457M ▼
Q3-2024 $220.364K $37.812M $23.92M $13.892M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-3.718M ▼ $-7.468M ▼ $-755.075K ▼ $3.089M ▲ $-5.566M ▼ $-8.223M ▼
Q2-2025 $-256.691K ▲ $-3.452M ▲ $-316.648K ▲ $-702.098K ▼ $-4.473M ▼ $-3.769M ▲
Q1-2025 $-5.681M ▼ $-6.103M ▼ $-872.804K ▼ $22.406M ▲ $15.455M ▲ $-6.976M ▼
Q4-2024 $-1.923M ▲ $-3.262M ▼ $-125.142K ▼ $3.411M ▲ $524.523K ▲ $-3.387M ▼
Q3-2024 $-3.245M $-2.547M $1.703M $722.336K $-447.883K $-843.98K

Revenue by Products

Product Q1-2025Q2-2025Q3-2025
System Sales Member
System Sales Member
 $0 ▲$10.00M ▲$10.00M ▲

Five-Year Company Overview

Income Statement

Income Statement SSII still looks like a very early-stage commercial company. Revenue has only just begun to appear and remains tiny, while operating costs are much larger than sales. That means the business is running at a clear loss, and has been for years. There are some signs of gradual progress as revenue starts to show up, but the company is still firmly in the “investment and build‑out” phase rather than a scale, profit, or even break‑even phase. Profitability currently depends entirely on achieving meaningful growth in system sales and recurring usage over time, which is still ahead of them rather than visible in the historical numbers.

Balance Sheet

Balance Sheet The balance sheet is small and thin, which is typical of an early-stage medical device innovator but also a constraint. Assets and equity have been creeping up, but both remain modest. Cash is limited, and there is some debt that has grown alongside the asset base. This points to a company that has begun to invest in commercialization but does not yet have a large financial cushion. Future growth and ongoing development are likely to require additional outside financing unless revenue ramps quickly.

Cash Flow

Cash Flow Cash flow from the core business is negative, reflecting ongoing operating losses. Free cash flow is also negative, but not because of heavy factory or equipment spending; it is mainly the cost of running and building the business. In practical terms, SSII is burning cash to fund R&D, commercialization, and overhead, and is not yet self‑funding. How the company manages its cash runway and access to new capital will be a key issue until the business model scales up.

Competitive Edge

Competitive Edge Strategically, SSII is trying to carve out a differentiated place in surgical robotics by focusing on affordability and emerging markets, starting with a strong base in India. Its system is designed to be meaningfully cheaper than dominant Western platforms while still offering advanced features like high‑quality 3D visualization, flexible multi‑arm robotics, and ergonomic surgeon controls. The company is also positioning itself as a specialist in robotic cardiac surgery and building a full ecosystem around its platform, from instruments to training and digital connectivity. Against this, SSII is tiny compared to global leaders, lacks broad approvals in major developed markets, and still has to prove long‑term reliability, support, and clinical adoption at scale. When and if it enters markets dominated by incumbents, it will face intense competition, even if its price point is attractive. Its competitive story is promising but remains early and unproven at global scale.

Innovation and R&D

Innovation and R&D Innovation is the core of SSII’s story. The main platform is built to be modular and open, with room to add new instruments, procedures, and digital capabilities over time. The company is investing in telesurgery, tele‑proctoring, and mixed‑reality training, and it is working on expanding its procedure range, including more delicate areas such as pediatric surgery. It is also exploring AI‑driven planning and visualization, which could further differentiate its ecosystem if executed well. Regulatory progress is a major innovation milestone: approvals in the U.S. and Europe are still in the future and represent both an opportunity and a risk. The presence of notable industry figures on the board supports the idea that the technology is credible, but the path from strong R&D to consistently adopted products across many hospitals is long and uncertain.

Summary

Overall, SSII looks like a classic high‑innovation, early‑stage medical technology company: technologically ambitious, commercially young, and financially fragile. The financials show a business that is only just starting to generate revenue and still relying on external funding to cover ongoing losses and cash burn. Strategically, the company’s focus on affordable robotic surgery for emerging markets, plus an integrated ecosystem and telesurgery capabilities, could give it a differentiated niche if it can execute. The key uncertainties lie in scaling sales, obtaining and maintaining regulatory approvals in major markets, building a strong installed base, and managing cash needs along the way. SSII’s future will largely be determined by whether it can turn its innovation and cost advantage into sustained clinical adoption and a self‑funding business model before financial constraints bite too hard.

NEWS

November 6, 2025 · 8:32 AM UTC

SS Innovations Announces Successful Completion of First Telesurgery Performed with the Company's SSi Mantra Tele Surgeon Console

Read more

November 6, 2025 · 8:30 AM UTC

SS Innovations Announces Successful Completion of First Telesurgery Performed with the Company's SSi Mantra Tele Surgeon Console

Read more

October 28, 2025 · 5:00 PM UTC

SS Innovations Reports Third Quarter 2025 Financial Results

Read more

October 28, 2025 · 4:30 PM UTC

SS Innovations Reports Third Quarter 2025 Financial Results

Read more

October 21, 2025 · 8:32 AM UTC

SS Innovations to Participate in Upcoming Investor Conferences

Read more